1. Home
  2. UDMY vs LQDA Comparison

UDMY vs LQDA Comparison

Compare UDMY & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UDMY
  • LQDA
  • Stock Information
  • Founded
  • UDMY 2009
  • LQDA 2004
  • Country
  • UDMY United States
  • LQDA United States
  • Employees
  • UDMY N/A
  • LQDA N/A
  • Industry
  • UDMY Other Consumer Services
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • UDMY Real Estate
  • LQDA Health Care
  • Exchange
  • UDMY Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • UDMY 1.2B
  • LQDA 957.2M
  • IPO Year
  • UDMY 2021
  • LQDA 2018
  • Fundamental
  • Price
  • UDMY $7.45
  • LQDA $14.40
  • Analyst Decision
  • UDMY Buy
  • LQDA Strong Buy
  • Analyst Count
  • UDMY 10
  • LQDA 7
  • Target Price
  • UDMY $10.95
  • LQDA $26.67
  • AVG Volume (30 Days)
  • UDMY 601.9K
  • LQDA 768.6K
  • Earning Date
  • UDMY 02-13-2025
  • LQDA 03-12-2025
  • Dividend Yield
  • UDMY N/A
  • LQDA N/A
  • EPS Growth
  • UDMY N/A
  • LQDA N/A
  • EPS
  • UDMY N/A
  • LQDA N/A
  • Revenue
  • UDMY $776,168,000.00
  • LQDA $15,610,000.00
  • Revenue This Year
  • UDMY $9.33
  • LQDA N/A
  • Revenue Next Year
  • UDMY $3.30
  • LQDA $213.65
  • P/E Ratio
  • UDMY N/A
  • LQDA N/A
  • Revenue Growth
  • UDMY 10.14
  • LQDA N/A
  • 52 Week Low
  • UDMY $6.67
  • LQDA $8.26
  • 52 Week High
  • UDMY $14.74
  • LQDA $16.99
  • Technical
  • Relative Strength Index (RSI)
  • UDMY 30.03
  • LQDA 75.26
  • Support Level
  • UDMY $8.07
  • LQDA $11.34
  • Resistance Level
  • UDMY $8.71
  • LQDA $12.58
  • Average True Range (ATR)
  • UDMY 0.29
  • LQDA 0.56
  • MACD
  • UDMY -0.13
  • LQDA 0.22
  • Stochastic Oscillator
  • UDMY 0.88
  • LQDA 98.71

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The Company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: